Peptide drugs, clinical trials, and medical applications
Peptide therapeutics for Alzheimer’s, Parkinson’s, and ALS face the blood-brain barrier — the central unsolved challenge in CNS drug delivery. Three BBB-penetration strategies are in clinical testing, but no peptide has yet shown Phase III efficacy. Rare neurodegenerative diseases may be the breakthrough indication.
Neoantigen peptide vaccines have entered Phase II with a 67% response rate in melanoma combination therapy. While mRNA approaches grab headlines, peptide vaccines offer distinct advantages: simpler manufacturing, ambient-temperature stability, and a century of regulatory precedent.
Oral peptide delivery remains the holy grail of peptide therapeutics. With Rybelsus generating $4.2B in 2025 and $1.2B in new venture funding, technologies from SNAC to ionic liquids are progressively cracking the bioavailability barrier.
GLP-1/GLP-2 co-agonists like dapiglutide are advancing through Phase II with improved tolerability profiles and complementary gut-barrier benefits. As the obesity market races toward $100B, multi-receptor agonism represents the next competitive frontier.
Antimicrobial peptides are finally moving from academic curiosity to clinical reality. With AMR on the rise, AMPs offer a fundamentally different mechanism that bacteria struggle to resist.
GLP-1 agonists are moving beyond diabetes and obesity into cardiovascular, neurodegenerative, and addiction indications. Here’s what the peptide science tells us about the next decade.